Cel
The infectious diseases burden imposed by the parasites of Trypanosomatidae family represents a huge problem on people’s lives in countries where these diseases are endemic. Problems associated with existing drugs include inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. New drugs are urgently needed now and in the foreseeable future. The New Medicine for Trypanosomatid Infections (NMTrypI) consortium uses a highly interdisciplinary approach to optimize pteridine, benzothiazole and miltefosine derivatives, as well as natural products against Trypanosomatids. The lead compounds target mechanisms that are associated with protozoa virulence and pathogenicity. The major objectives of this 3-year project are: i) development of drug leads which may be used in combination with a known or an investigational drugs, by using a common drug discovery platform established by experts in their respective fields, ii) development of pharmacodynamic biomarkers enabling the proteomic profiling of compound efficacy and early identification of drug resistance. NMTrypI addresses sleeping sickness, leishmaniasis, and Chagas disease. The partners are SMEs (5) and academics (8) in Europe and in disease-endemic countries (Italy, Greece, Portugal, Sudan, and Brazil). The new platform enables high throughput screening of compound libraries, lead development, testing in relevant animal models, as well as toxicology and safety testing. NMTrypI will translate drug leads into drug candidacy through 6 scientific work packages (WPs1-6) supported by two transversal WPs dedicated to project dissemination and management. The major strength of the consortium lies in the complementary partners’expertise and the integrated platform that will provide:
- at least 1-2 innovative, less toxic and safer drug candidates for Trypanosomatid infections compared to existing ones,
- early phase biomarkers for efficacy prediction (overall improved efficacy and safety)
Dziedzina nauki
- medical and health sciencesclinical medicinepsychiatrysleep disorders
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistance
- medical and health sciencesbasic medicinetoxicology
Zaproszenie do składania wniosków
FP7-HEALTH-2013-INNOVATION-1
Zobacz inne projekty w ramach tego zaproszenia
System finansowania
CP-FP - Small or medium-scale focused research projectKoordynator
41121 Modena
Włochy
Zobacz na mapie
Uczestnicy (13)
22525 Hamburg
Zobacz na mapie
20359 Hamburg
Zobacz na mapie
4200 135 Porto
Zobacz na mapie
53100 Siena
Zobacz na mapie
69118 Heidelberg
Zobacz na mapie
41126 Modena
Zobacz na mapie
11111 Khartoum
Zobacz na mapie
SL6 6QH Maidenhead
Zobacz na mapie
11635 Athina
Zobacz na mapie
28040 Madrid
Zobacz na mapie
Zakończenie uczestnictwa
1000 Bruxelles
Zobacz na mapie
13083 100 Campinas
Zobacz na mapie
80686 Munchen
Zobacz na mapie